^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Imjudo (tremelimumab-actl)

    i
    Other names: PF06753388, CP675206, CP 675206, CP-675206, CP-675,206, CP-675, PF-06753388, CP 675, CP675, PF 06753388
    Company:
    AstraZeneca, Pfizer
    Drug class:
    CTLA4 inhibitor
    Related drugs:
    13h
    TREMENDOUS-2: Durvalumab and Tremelimumab With Lenvatinib as First-line Treatment in Patients With Unresectable Hepatocellular Carcinoma (clinicaltrials.gov)
    P2, N=114, Active, not recruiting, AstraZeneca | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    Imfinzi (durvalumab) • Lenvima (lenvatinib) • Imjudo (tremelimumab-actl)
    16h
    REFINE-IO: An Observational Study to Learn More About How Well a Treatment Works When Given After Treatment With Atezolizumab and Bevacizumab or Another Similar Combination of Drugs in Adults With Liver Cancer That Cannot be Treated With Surgery (clinicaltrials.gov)
    P=N/A, N=300, Active, not recruiting, Bayer | Recruiting --> Active, not recruiting | Trial primary completion date: Nov 2026 --> Dec 2025
    Enrollment closed • Trial primary completion date • Checkpoint inhibition
    |
    Avastin (bevacizumab) • Tecentriq (atezolizumab) • Imfinzi (durvalumab) • Imjudo (tremelimumab-actl)
    2d
    An unusual presentation of Hepatocellular Carcinoma: Isolated bile duct involvement without detectable hepatic mass. (PubMed, Z Gastroenterol)
    Given the advanced stage of disease, systemic immunotherapy with tremelimumab and durvalumab was initiated. This case underscores the critical role of a multimodal diagnostic approach in atypical presentations of HCC to enable accurate diagnosis and appropriate therapeutic decision-making.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    TP53 (Tumor protein P53) • GPC3 (Glypican 3)
    |
    Imfinzi (durvalumab) • Imjudo (tremelimumab-actl)
    2d
    NCI-2018-01415: Radiation Therapy and Durvalumab With or Without Tremelimumab in Treating Participants With Unresectable, Locally Advanced, or Metastatic Bladder Cancer (clinicaltrials.gov)
    P2, N=13, Active, not recruiting, Jonsson Comprehensive Cancer Center | Trial completion date: Jan 2027 --> Jan 2028 | Trial primary completion date: Jan 2026 --> Jan 2027
    Trial completion date • Trial primary completion date • Checkpoint inhibition
    |
    Imfinzi (durvalumab) • Imjudo (tremelimumab-actl)
    6d
    RESOLVE: Tremelimumab + Durvalumab(MEDI4736)+ Belinostat in Urothelial Carcinoma (clinicaltrials.gov)
    P1, N=9, Active, not recruiting, University of Utah | Trial primary completion date: Apr 2026 --> Aug 2026
    Trial primary completion date
    |
    Imfinzi (durvalumab) • Imjudo (tremelimumab-actl) • Beleodaq (belinostat)
    6d
    Durvalumab (MEDI4736) and Tremelimumab for Hepatocellular Carcinoma in Patients Listed for a Liver Transplant (clinicaltrials.gov)
    P2, N=8, Terminated, University of Cincinnati | N=30 --> 8 | Active, not recruiting --> Terminated; The study is closing due to low enrollment and feasibility of the study.
    Enrollment change • Trial termination
    |
    Imfinzi (durvalumab) • Imjudo (tremelimumab-actl)
    8d
    IOSPHERE: Evaluation of SIRT Followed by Immunotherapy for Treatment of Hepatocellular Carcinoma With Portal Vein Thrombosis (clinicaltrials.gov)
    P2, N=80, Recruiting, Center Eugene Marquis | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Imfinzi (durvalumab) • Imjudo (tremelimumab-actl)
    9d
    Durvalumab (MEDI4736) and Tremelimumab and Radiation Therapy in Hepatocellular Carcinoma and Biliary Tract Cancer (clinicaltrials.gov)
    P2, N=37, Active, not recruiting, Massachusetts General Hospital | Recruiting --> Active, not recruiting | N=70 --> 37 | Trial completion date: Oct 2026 --> Apr 2026
    Enrollment closed • Enrollment change • Trial completion date
    |
    Imfinzi (durvalumab) • Imjudo (tremelimumab-actl)
    9d
    Durvalumab and tremelimumab combination therapy achieved remarkable response in primary hepatic undifferentiated carcinoma with high PD-L1 expression. (PubMed, Clin J Gastroenterol)
    Shortly after treatment, the patient developed cranial nerve palsies (III, VII, VIII), suspected to represent either an immune-related adverse event or Ramsay Hunt syndrome; his symptoms improved with prednisolone and valaciclovir, allowing Dur/Tre to be resumed. To our knowledge, this is the first report of primary hepatic undifferentiated carcinoma with high PD-L1 expression demonstrating a sustained response to Dur/Tre. This case suggests that PD-L1 expression may serve as a potential biomarker for predicting ICI responsiveness in this rare and aggressive tumor.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression • PD-L1 overexpression
    |
    Imfinzi (durvalumab) • Imjudo (tremelimumab-actl) • valacyclovir
    19d
    DUMELEP: Durvalumab/Tremelimumab in Neoadjuvant and Adjuvant Setting in Patients With HCC Treated by by Percutaneous Ablation Procedure (clinicaltrials.gov)
    P2, N=30, Active, not recruiting, Assistance Publique - Hôpitaux de Paris | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    PD-L2 (Programmed Cell Death 1 Ligand 2) • TNFRSF9 (TNF Receptor Superfamily Member 9)
    |
    Imfinzi (durvalumab) • Imjudo (tremelimumab-actl)
    21d
    Durvalumab ± Tremelimumab in Combination With Platinum Based Chemotherapy in Untreated Extensive-Stage Small Cell Lung Cancer (CASPIAN) (clinicaltrials.gov)
    P3, N=987, Active, not recruiting, AstraZeneca | Trial completion date: Dec 2025 --> Dec 2026
    Trial completion date
    |
    cisplatin • carboplatin • Imfinzi (durvalumab) • Imjudo (tremelimumab-actl) • etoposide IV
    22d
    Durvalumab and Tremelimumab for Pediatric Malignancies (clinicaltrials.gov)
    P1/2, N=50, Active, not recruiting, AstraZeneca | Trial completion date: Dec 2024 --> Dec 2026
    Trial completion date
    |
    Imfinzi (durvalumab) • Imjudo (tremelimumab-actl)